In addition, serum IL-2 and soluble IL-2 receptor alpha (sIL-2rα) increased as patients with MPNs progressed to advanced clinical stages [13], and serum IL-2, sIL-2rα, and IL-6 levels were positively correlated with bone marrow neovascularization, indicating that increased inflammatory responses may be connected to the course of MPN disease [14], suggesting that MPN patients may benefit from using cytokines as a tool for illness monitoring [15]. The gene discussed is IL2; the disease is myeloproliferative neoplasm.